AR044400A1 - PROCESSES FOR THE PREPARATION OF PIRIMIDINE DERIVATIVES - Google Patents

PROCESSES FOR THE PREPARATION OF PIRIMIDINE DERIVATIVES

Info

Publication number
AR044400A1
AR044400A1 ARP040101733A ARP040101733A AR044400A1 AR 044400 A1 AR044400 A1 AR 044400A1 AR P040101733 A ARP040101733 A AR P040101733A AR P040101733 A ARP040101733 A AR P040101733A AR 044400 A1 AR044400 A1 AR 044400A1
Authority
AR
Argentina
Prior art keywords
preparation
hydrogen
processes
compounds
unsubstituted
Prior art date
Application number
ARP040101733A
Other languages
Spanish (es)
Original Assignee
Ciba Sc Holding Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Sc Holding Ag filed Critical Ciba Sc Holding Ag
Publication of AR044400A1 publication Critical patent/AR044400A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe un proceso para la preparación de compuestos de la fórmula (1), a partir de la reacción de los compuestos seleccionados del grupo de fórmulas (2), para formar un compuesto de la fórmula (3), en las cuales en cada caso R1, R2 y R3 son cada uno, independientemente entre sí, un radical orgánico sin sustituir o sustituido; R4 es hidrógeno, alquilo C1-8, alcoxilo C1-8, fenoxilo o benciloxilo sin sustituir o sustituidos, o halógeno; Y1 e Y2 son cada uno, independientemente del otro, hidrógeno o un grupo protector, o Y1 e Y2 conjuntamente son un puente de protección; y X1 es hidrógeno, un radical orgánico o un catión; y también compuestos intermedios novedosos.A process for the preparation of compounds of the formula (1) is described, from the reaction of the compounds selected from the group of formulas (2), to form a compound of the formula (3), in which in each case R1, R2 and R3 are each, independently of each other, an unsubstituted or substituted organic radical; R4 is hydrogen, C1-8 alkyl, C1-8 alkoxy, unsubstituted or substituted phenoxy or benzyloxy, or halogen; Y1 and Y2 are each, independently of the other, hydrogen or a protecting group, or Y1 and Y2 together are a protection bridge; and X1 is hydrogen, an organic radical or a cation; and also novel intermediate compounds.

ARP040101733A 2003-05-21 2004-05-19 PROCESSES FOR THE PREPARATION OF PIRIMIDINE DERIVATIVES AR044400A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03405355 2003-05-21

Publications (1)

Publication Number Publication Date
AR044400A1 true AR044400A1 (en) 2005-09-14

Family

ID=33462271

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101733A AR044400A1 (en) 2003-05-21 2004-05-19 PROCESSES FOR THE PREPARATION OF PIRIMIDINE DERIVATIVES

Country Status (2)

Country Link
AR (1) AR044400A1 (en)
WO (1) WO2004103977A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1015744C2 (en) 2000-07-19 2002-01-22 Dsm Nv Process for the preparation of 2- (6-substituted-1,3-dioxan-4-yl) acetic acid derivatives.
MXPA04000322A (en) 2001-07-13 2005-09-08 Astrazeneca Uk Ltd Preparation of aminopyrimidine compounds.
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
KR101060215B1 (en) 2002-12-16 2011-08-29 아스트라제네카 유케이 리미티드 Process for preparing pyrimidine compound
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2005054207A1 (en) * 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
CN100351240C (en) * 2005-01-19 2007-11-28 安徽省庆云医药化工有限公司 Rosuvastatin calcium synthesis method
US7612203B2 (en) * 2005-02-22 2009-11-03 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
WO2007040940A1 (en) * 2005-10-03 2007-04-12 Teva Pharmaceutical Industries Ltd. Diastereomeric purification of rosuvastatin
WO2007099561A1 (en) * 2006-02-27 2007-09-07 Cadila Healthcare Limited Process for preparing rosuvastatin calcium
WO2009157014A2 (en) * 2008-01-30 2009-12-30 Cadila Healthcare Limited A process for preparing hmg-coa reductase inhibitors and intermediates
EP2298745B1 (en) 2008-05-27 2014-09-03 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
CN101955463B (en) * 2010-08-04 2012-01-04 重庆博腾制药科技股份有限公司 Method for preparing rosuvastatin calcium intermediate
HU230987B1 (en) * 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Process for the preparation of pharmaceutical intermediates with high purity
CN102617481A (en) * 2012-03-16 2012-08-01 湖南欧亚生物有限公司 Preparation method of rosuvastatin calcium
CN102633727A (en) * 2012-04-01 2012-08-15 浙江工业大学 Synthetic method of 2-methylthio-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-5-methyl carbonate
CN103113356A (en) * 2013-03-07 2013-05-22 上海现代制药股份有限公司 Method for preparing rosuvastatin calcium intermediate
US9850213B2 (en) * 2013-11-25 2017-12-26 Jiangxi Boya Seehot Pharmaceutical Co., Ltd. Method for preparing rosuvastatin sodium
CN103804414B (en) * 2014-03-07 2016-04-13 凯莱英医药集团（天津）股份有限公司 For the preparation of rosuvastain calcium midbody compound and prepared the method for rosuvastain calcium by it
PT3115367T (en) * 2014-03-07 2018-01-04 Asymchem Laboratories Fuxin Co Ltd Intermediate compound for preparing rosuvastatin calcium and method for preparing rosuvastatin calcium therefrom
CN104059024B (en) * 2014-06-16 2016-04-06 浙江大学 The preparation method of Rosuvastatin intermediate and midbody compound
CN105175345B (en) * 2015-09-22 2018-05-22 上海应用技术学院 A kind of method for preparing Rosuvastatin intermediate
CN106397335A (en) * 2016-08-31 2017-02-15 湖北祥云(集团)化工股份有限公司 Preparation method of rosuvastatin intermediate
CN108191772A (en) * 2017-12-28 2018-06-22 江苏悦兴医药技术有限公司 The synthetic method of rosuvastain calcium intermediate impurities
CN115819408B (en) * 2022-10-21 2024-09-06 宿迁阿尔法科技有限公司 Method for synthesizing rosuvastatin key intermediate with high selectivity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3105354B2 (en) * 1991-07-03 2000-10-30 三井化学株式会社 Developer composition, aqueous suspension, and developer sheet for pressure-sensitive copying paper using the same

Also Published As

Publication number Publication date
WO2004103977A2 (en) 2004-12-02
WO2004103977A3 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
AR044400A1 (en) PROCESSES FOR THE PREPARATION OF PIRIMIDINE DERIVATIVES
MXPA04001016A (en) Sulfonamide derivatives as gamma secretase inhibitors.
ES2221440T3 (en) AMINOPHENOXYACETIC ACID DERIVATIVES AS NEUROPROTECTORS.
CO5050332A1 (en) FUNGICIDE COMPOSITIONS THAT INCLUDE 2-METOXIBENZOPHENONES
EA200800285A1 (en) NEW DERIVATIVES 2,4-DIANILINOPIRIMIDINES, THEIR PRODUCTION, MEDICINES, PHARMACEUTICAL COMPOSITIONS, CONTAINING INDICATED DERIVATIVES, AND THEIR APPLICATION, IN PARTICULAR, AS THE PROTECTIVE.
CO5580803A2 (en) DERIVATIVES OF PIPERIDIN-BENCENSULFONAMIDE
AR052866A1 (en) SUBSTITUTED MONOCICLIC PHENYL-METANONES
CO4970713A1 (en) DERIVATIVES OF CARBOXAMIDOTIAZOLES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
AR034268A1 (en) COMPOUNDS DERIVED FROM PIPERIDINE, ITS USE IN PREPARATION OF MEDICINES, PHARMACEUTICAL COMPOSITION, TREATMENT METHOD AND PROCESS FOR PREPARATION
DE60307179D1 (en) UV radiation protective compositions
CO5611126A2 (en) INDOLINONA DERIVATIVES USEFUL AS INHIBITORS OF PROTEIN CINASA
AR041297A1 (en) DERIVATIVES OF 4-PIRROLIDINO- FENIL- BENCIL ETER
BR9612099A (en) Process for preparing a compound derived from piperidine, regioisomer, process for preparing a regioisomer, derived from 4- (alpha, alpha, di-substituted) toluic acid and 4- (alpha, alpha-di-unsubstituted) toluic acid.
AR040489A1 (en) COMPOUNDS DERIVED FROM 3-PHENYL-PROPIONAMIDE, 3-PHENYL-ACRYLAMIDE AND 3-PHENYL-PROPINAMID, ITS USE FOR THE PREPARATION OF MEDICINES, A PROCESS TO PREPARE THE COMPOUNDS AND MEDICINES CONTAINING THEM
ECSP045278A (en) OXO-AZABYCLIC COMPOUNDS
AR042362A1 (en) DERIVATIVES OF 3H-QUINAZOLIN-4-ONA, PROCESS OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PE20030705A1 (en) 17BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN-DEPENDENT DISEASES
NO20040388L (en) Process for the preparation of beraprost and its salts, as well as compounds which are intermediates in the process
CO5601030A2 (en) DERIVATIVES OF QUINOLINONA / BENZOXAZINONA AND USES OF THE SAME
CO5540385A2 (en) OXAZOL ARILPROPIONIC ACID CHIRAL DERIVATIVES, THEIR SYNTHESIS METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BR0212982A (en) Process for preparing a compound, and, compound
NO20050612L (en) Pyrrolidine derivatives as oxytocin antagonists
NO20060718L (en) Substituted thiophones and their use
NO20061045L (en) imidazole
ATE372332T1 (en) METHOD FOR PRODUCING INTERMEDIATE COMPOUNDS IN THE PRODUCTION OF DISCODERMOLID AND DISCODERMOLID ANALOGS

Legal Events

Date Code Title Description
FB Suspension of granting procedure